MA30153B1 - Anticorps anti-ox40l et methodes correspondantes - Google Patents

Anticorps anti-ox40l et methodes correspondantes

Info

Publication number
MA30153B1
MA30153B1 MA31104A MA31104A MA30153B1 MA 30153 B1 MA30153 B1 MA 30153B1 MA 31104 A MA31104 A MA 31104A MA 31104 A MA31104 A MA 31104A MA 30153 B1 MA30153 B1 MA 30153B1
Authority
MA
Morocco
Prior art keywords
corresponding methods
ox40l antibodies
ox40l
antibodies
methods
Prior art date
Application number
MA31104A
Other languages
English (en)
French (fr)
Inventor
Flavius Martin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA30153B1 publication Critical patent/MA30153B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA31104A 2005-12-16 2008-07-11 Anticorps anti-ox40l et methodes correspondantes MA30153B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75137705P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
MA30153B1 true MA30153B1 (fr) 2009-01-02

Family

ID=38616368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31104A MA30153B1 (fr) 2005-12-16 2008-07-11 Anticorps anti-ox40l et methodes correspondantes

Country Status (18)

Country Link
US (2) US7812133B2 (OSRAM)
EP (1) EP1973949A2 (OSRAM)
JP (1) JP2009519718A (OSRAM)
KR (1) KR20080080639A (OSRAM)
CN (1) CN101374865A (OSRAM)
AR (1) AR057253A1 (OSRAM)
AU (1) AU2006343459A1 (OSRAM)
BR (1) BRPI0621065A2 (OSRAM)
CA (1) CA2633602A1 (OSRAM)
CR (1) CR10069A (OSRAM)
EC (1) ECSP088543A (OSRAM)
IL (1) IL191820A0 (OSRAM)
MA (1) MA30153B1 (OSRAM)
NO (1) NO20083147L (OSRAM)
RU (1) RU2426744C2 (OSRAM)
TW (1) TW200732349A (OSRAM)
WO (1) WO2007133290A2 (OSRAM)
ZA (1) ZA200804868B (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
EP2041756B1 (en) 2006-07-14 2015-05-13 FEI Company A multi-source plasma focused ion beam system
US20100136030A1 (en) * 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
US20120020960A1 (en) * 2010-07-26 2012-01-26 Baylor Research Institute Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
ES2630328T3 (es) 2010-08-23 2017-08-21 Board Of Regents, The University Of Texas System Anticuerpos anti-OX40 y procedimientos de uso de los mismos
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
DK2699601T3 (en) 2011-04-21 2018-04-23 Bristol Myers Squibb Co ANTIBODY POLYPEPTIDES ANTAGONIZING CD40
EP2748199B1 (en) * 2011-08-23 2019-08-28 Board of Regents, The University of Texas System Anti-ox40 antibodies and methods of using the same
CN105744944B (zh) * 2013-09-09 2020-07-07 卡尼姆盖德治疗学公司 免疫系统调节器
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017165652A (ja) * 2014-06-30 2017-09-21 国立大学法人東北大学 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
CN107074951B (zh) * 2014-08-04 2021-08-03 贝勒研究院 拮抗性抗-ox40l抗体及其使用方法
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
KR20250005465A (ko) * 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
ES2853582T3 (es) 2015-03-06 2021-09-16 Canimguide Therapeutics Ab Moduladores del sistema inmune y composiciones
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
WO2017178869A1 (es) * 2016-04-15 2017-10-19 Pontificia Universidad Católica De Chile Composición farmacéutica para aminorar los síntomas y enfermedad de la infección respiratoria causada por el metapneumovirus humano (hmpv), que comprende al menos un agente que neutraliza la función de las moléculas tslp, y/o tslpr, y/o ox40l y/o cd177, y un excipiente farmacéuticamente aceptable, y su uso
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN117736325A (zh) 2016-08-09 2024-03-22 科马布有限公司 分离抗体及其应用
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019100320A1 (en) 2017-11-24 2019-05-31 Eucure (Beijing) Biopharma Co., Ltd Anti-ox40 antibodies and uses thereof
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
AU2020480890A1 (en) * 2020-12-09 2023-07-27 Hk Inno.N Corporation ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFα BISPECIFIC ANTIBODY, AND USES THEREOF
JP2024530954A (ja) * 2021-08-10 2024-08-27 カイマブ・リミテッド アトピー性皮膚炎の処置
EP4476256A1 (en) * 2022-02-09 2024-12-18 Petmedix Ltd. Therapeutic antibodies
WO2025090570A1 (en) * 2023-10-23 2025-05-01 Abcellera Biologics Inc. Anti-ox40l antibodies and methods of use
WO2025158009A1 (en) * 2024-01-26 2025-07-31 Almirall S.A. Bispecific molecules and methods of treatment using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
AU7522401A (en) * 2000-06-06 2001-12-17 Idec Pharma Corp Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
FR2822846B1 (fr) * 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
JP3926596B2 (ja) 2001-09-28 2007-06-06 独立行政法人科学技術振興機構 Ｏｘ４０ｌ遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物
US20040009174A1 (en) * 2001-12-18 2004-01-15 Arndt Gregory Martin Method of treating asthma
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
MXPA06010887A (es) * 2004-03-23 2007-03-08 Amgen Inc Anticuerpos monoclonales especificos para ox4ol (cd 134l) humano.
JP2006081061A (ja) * 2004-09-13 2006-03-23 Alpine Electronics Inc 音声出力装置及び音声／映像出力装置
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US20100136030A1 (en) 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases

Also Published As

Publication number Publication date
WO2007133290A3 (en) 2008-01-10
US20100272738A1 (en) 2010-10-28
KR20080080639A (ko) 2008-09-04
WO2007133290A8 (en) 2008-03-27
JP2009519718A (ja) 2009-05-21
WO2007133290A2 (en) 2007-11-22
IL191820A0 (en) 2008-12-29
RU2426744C2 (ru) 2011-08-20
RU2008129111A (ru) 2010-01-27
US7812133B2 (en) 2010-10-12
BRPI0621065A2 (pt) 2011-11-29
AU2006343459A1 (en) 2007-11-22
ZA200804868B (en) 2009-10-28
TW200732349A (en) 2007-09-01
EP1973949A2 (en) 2008-10-01
ECSP088543A (es) 2008-07-30
CA2633602A1 (en) 2007-11-22
CR10069A (es) 2008-10-10
CN101374865A (zh) 2009-02-25
NO20083147L (no) 2008-09-16
AR057253A1 (es) 2007-11-21
US20090053230A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EP1896073A4 (en) ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND USES
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
EA200702643A1 (ru) Антитела, связывающие tweak
TW200626171A (en) Fixed dosing of HER antibodies
EA200701918A1 (ru) Белок липокалин
TW200709817A (en) Platform antibody compositions
DK1804589T3 (da) Fedtsammensætninger
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
EA200702193A1 (ru) Гликозилирование белков
ATE499341T1 (de) 5-(2,2-dimethyl-cyclopropyl)-3-methylpent-2- ennitril als geruchs- und geschmacksstoff
FR2894983B1 (fr) Test de caracterisation des anticorps.
WO2007073567A3 (en) Compositions and methods of modulating the immune response
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13